We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 222% below its sector, cheaper than its peers on earnings.
Beijing Hotgen Biotech Co., Ltd. specializes in the complete process, from research and development to manufacturing and sales, of in-vitro diagnostic (IVD) solutions for medical and public safety purposes within the biomedical field. Their comprehensive range of products incorporates cutting-edge technologies like drug detection, CDC-compliant methods, up-conversion luminescence, colloidal gold, CLIA, sugar capture, microfluidics, and gene detection. These advanced diagnostic tools are designed to identify a broad spectrum of targets, including intestinal microorganisms, pathogens causing gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, various infectious diseases, Ebola virus antigens, biological warfare agents, other microorganisms, and mycotoxins. The company, founded in 2005, is headquartered in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 688068.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
